nodes	percent_of_prediction	percent_of_DWPC	metapath
Abacavir—Nucleoside Analog—Azathioprine—systemic scleroderma	0.648	1	CiPCiCtD
Abacavir—UGT1A1—Mycophenolic acid—systemic scleroderma	0.156	0.642	CbGbCtD
Abacavir—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0874	0.358	CbGbCtD
Abacavir—ADH6—digestive system—systemic scleroderma	0.00231	0.327	CbGeAlD
Abacavir—ADH6—lung—systemic scleroderma	0.00193	0.273	CbGeAlD
Abacavir—ADK—smooth muscle tissue—systemic scleroderma	0.000678	0.0959	CbGeAlD
Abacavir—ADK—skin of body—systemic scleroderma	0.00067	0.0947	CbGeAlD
Abacavir—UGT1A1—digestive system—systemic scleroderma	0.000528	0.0747	CbGeAlD
Abacavir—ADK—tendon—systemic scleroderma	0.00051	0.0721	CbGeAlD
Abacavir—ADK—lung—systemic scleroderma	0.000447	0.0632	CbGeAlD
Abacavir—Dyspnoea—Leflunomide—systemic scleroderma	0.000101	0.000996	CcSEcCtD
Abacavir—Hypotension—Mycophenolic acid—systemic scleroderma	0.000101	0.000996	CcSEcCtD
Abacavir—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000101	0.000994	CcSEcCtD
Abacavir—Discomfort—Lisinopril—systemic scleroderma	0.0001	0.000989	CcSEcCtD
Abacavir—Lethargy—Methotrexate—systemic scleroderma	0.0001	0.000989	CcSEcCtD
Abacavir—Pancreatitis—Prednisone—systemic scleroderma	9.95e-05	0.000983	CcSEcCtD
Abacavir—Vomiting—Mometasone—systemic scleroderma	9.93e-05	0.000981	CcSEcCtD
Abacavir—Feeling abnormal—Azathioprine—systemic scleroderma	9.87e-05	0.000975	CcSEcCtD
Abacavir—Rash—Mometasone—systemic scleroderma	9.85e-05	0.000973	CcSEcCtD
Abacavir—Asthenia—Captopril—systemic scleroderma	9.85e-05	0.000972	CcSEcCtD
Abacavir—Dermatitis—Mometasone—systemic scleroderma	9.84e-05	0.000972	CcSEcCtD
Abacavir—Decreased appetite—Leflunomide—systemic scleroderma	9.83e-05	0.000971	CcSEcCtD
Abacavir—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	9.83e-05	0.000971	CcSEcCtD
Abacavir—Gastrointestinal pain—Azathioprine—systemic scleroderma	9.79e-05	0.000967	CcSEcCtD
Abacavir—Headache—Mometasone—systemic scleroderma	9.79e-05	0.000966	CcSEcCtD
Abacavir—Gastrointestinal disorder—Leflunomide—systemic scleroderma	9.76e-05	0.000964	CcSEcCtD
Abacavir—Insomnia—Mycophenolic acid—systemic scleroderma	9.76e-05	0.000964	CcSEcCtD
Abacavir—Fatigue—Leflunomide—systemic scleroderma	9.75e-05	0.000963	CcSEcCtD
Abacavir—Oedema—Lisinopril—systemic scleroderma	9.72e-05	0.00096	CcSEcCtD
Abacavir—Anaphylactic shock—Lisinopril—systemic scleroderma	9.72e-05	0.00096	CcSEcCtD
Abacavir—Pruritus—Captopril—systemic scleroderma	9.71e-05	0.000959	CcSEcCtD
Abacavir—Paraesthesia—Mycophenolic acid—systemic scleroderma	9.69e-05	0.000957	CcSEcCtD
Abacavir—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	9.68e-05	0.000956	CcSEcCtD
Abacavir—Pain—Leflunomide—systemic scleroderma	9.67e-05	0.000955	CcSEcCtD
Abacavir—Infection—Lisinopril—systemic scleroderma	9.65e-05	0.000953	CcSEcCtD
Abacavir—Anaemia—Mycophenolate mofetil—systemic scleroderma	9.64e-05	0.000952	CcSEcCtD
Abacavir—Dyspnoea—Mycophenolic acid—systemic scleroderma	9.62e-05	0.00095	CcSEcCtD
Abacavir—Thrombocytopenia—Lisinopril—systemic scleroderma	9.51e-05	0.00094	CcSEcCtD
Abacavir—Neutropenia—Prednisone—systemic scleroderma	9.49e-05	0.000937	CcSEcCtD
Abacavir—Abdominal pain—Azathioprine—systemic scleroderma	9.47e-05	0.000935	CcSEcCtD
Abacavir—Body temperature increased—Azathioprine—systemic scleroderma	9.47e-05	0.000935	CcSEcCtD
Abacavir—Skin disorder—Lisinopril—systemic scleroderma	9.44e-05	0.000932	CcSEcCtD
Abacavir—Malaise—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000929	CcSEcCtD
Abacavir—Diarrhoea—Captopril—systemic scleroderma	9.39e-05	0.000927	CcSEcCtD
Abacavir—Decreased appetite—Mycophenolic acid—systemic scleroderma	9.38e-05	0.000926	CcSEcCtD
Abacavir—Vertigo—Mycophenolate mofetil—systemic scleroderma	9.37e-05	0.000926	CcSEcCtD
Abacavir—Leukopenia—Mycophenolate mofetil—systemic scleroderma	9.34e-05	0.000922	CcSEcCtD
Abacavir—Feeling abnormal—Leflunomide—systemic scleroderma	9.32e-05	0.00092	CcSEcCtD
Abacavir—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	9.31e-05	0.00092	CcSEcCtD
Abacavir—Fatigue—Mycophenolic acid—systemic scleroderma	9.3e-05	0.000919	CcSEcCtD
Abacavir—Nausea—Mometasone—systemic scleroderma	9.28e-05	0.000916	CcSEcCtD
Abacavir—Anorexia—Lisinopril—systemic scleroderma	9.26e-05	0.000915	CcSEcCtD
Abacavir—Gastrointestinal pain—Leflunomide—systemic scleroderma	9.25e-05	0.000913	CcSEcCtD
Abacavir—Pain—Mycophenolic acid—systemic scleroderma	9.23e-05	0.000911	CcSEcCtD
Abacavir—Hyperglycaemia—Prednisone—systemic scleroderma	9.16e-05	0.000904	CcSEcCtD
Abacavir—Cough—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000899	CcSEcCtD
Abacavir—Hypotension—Lisinopril—systemic scleroderma	9.08e-05	0.000897	CcSEcCtD
Abacavir—Dizziness—Captopril—systemic scleroderma	9.07e-05	0.000896	CcSEcCtD
Abacavir—Liver function test abnormal—Methotrexate—systemic scleroderma	9.06e-05	0.000895	CcSEcCtD
Abacavir—Convulsion—Mycophenolate mofetil—systemic scleroderma	9.04e-05	0.000893	CcSEcCtD
Abacavir—Depression—Prednisone—systemic scleroderma	9.02e-05	0.000891	CcSEcCtD
Abacavir—Urticaria—Leflunomide—systemic scleroderma	8.98e-05	0.000887	CcSEcCtD
Abacavir—Abdominal pain—Leflunomide—systemic scleroderma	8.94e-05	0.000883	CcSEcCtD
Abacavir—Body temperature increased—Leflunomide—systemic scleroderma	8.94e-05	0.000883	CcSEcCtD
Abacavir—Acute coronary syndrome—Prednisone—systemic scleroderma	8.92e-05	0.000881	CcSEcCtD
Abacavir—Feeling abnormal—Mycophenolic acid—systemic scleroderma	8.89e-05	0.000878	CcSEcCtD
Abacavir—Myalgia—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000877	CcSEcCtD
Abacavir—Arthralgia—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000877	CcSEcCtD
Abacavir—Neuropathy peripheral—Prednisone—systemic scleroderma	8.87e-05	0.000876	CcSEcCtD
Abacavir—Myocardial infarction—Prednisone—systemic scleroderma	8.87e-05	0.000876	CcSEcCtD
Abacavir—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	8.85e-05	0.000874	CcSEcCtD
Abacavir—Anxiety—Mycophenolate mofetil—systemic scleroderma	8.85e-05	0.000874	CcSEcCtD
Abacavir—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	8.84e-05	0.000873	CcSEcCtD
Abacavir—Hypersensitivity—Azathioprine—systemic scleroderma	8.82e-05	0.000871	CcSEcCtD
Abacavir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	8.82e-05	0.000871	CcSEcCtD
Abacavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	8.82e-05	0.000871	CcSEcCtD
Abacavir—Insomnia—Lisinopril—systemic scleroderma	8.79e-05	0.000868	CcSEcCtD
Abacavir—Discomfort—Mycophenolate mofetil—systemic scleroderma	8.78e-05	0.000867	CcSEcCtD
Abacavir—Paraesthesia—Lisinopril—systemic scleroderma	8.73e-05	0.000862	CcSEcCtD
Abacavir—Vomiting—Captopril—systemic scleroderma	8.72e-05	0.000862	CcSEcCtD
Abacavir—Dyspnoea—Lisinopril—systemic scleroderma	8.66e-05	0.000856	CcSEcCtD
Abacavir—Rash—Captopril—systemic scleroderma	8.65e-05	0.000854	CcSEcCtD
Abacavir—Dermatitis—Captopril—systemic scleroderma	8.64e-05	0.000854	CcSEcCtD
Abacavir—Headache—Captopril—systemic scleroderma	8.6e-05	0.000849	CcSEcCtD
Abacavir—Abdominal pain—Mycophenolic acid—systemic scleroderma	8.53e-05	0.000842	CcSEcCtD
Abacavir—Body temperature increased—Mycophenolic acid—systemic scleroderma	8.53e-05	0.000842	CcSEcCtD
Abacavir—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	8.51e-05	0.000841	CcSEcCtD
Abacavir—Oedema—Mycophenolate mofetil—systemic scleroderma	8.51e-05	0.000841	CcSEcCtD
Abacavir—Infection—Mycophenolate mofetil—systemic scleroderma	8.46e-05	0.000835	CcSEcCtD
Abacavir—Decreased appetite—Lisinopril—systemic scleroderma	8.45e-05	0.000834	CcSEcCtD
Abacavir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	8.39e-05	0.000828	CcSEcCtD
Abacavir—Fatigue—Lisinopril—systemic scleroderma	8.38e-05	0.000827	CcSEcCtD
Abacavir—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.35e-05	0.000825	CcSEcCtD
Abacavir—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.34e-05	0.000823	CcSEcCtD
Abacavir—Hypersensitivity—Leflunomide—systemic scleroderma	8.33e-05	0.000823	CcSEcCtD
Abacavir—Pancreatitis—Methotrexate—systemic scleroderma	8.32e-05	0.000821	CcSEcCtD
Abacavir—Pain—Lisinopril—systemic scleroderma	8.31e-05	0.000821	CcSEcCtD
Abacavir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000817	CcSEcCtD
Abacavir—Diarrhoea—Azathioprine—systemic scleroderma	8.19e-05	0.000809	CcSEcCtD
Abacavir—Nausea—Captopril—systemic scleroderma	8.15e-05	0.000805	CcSEcCtD
Abacavir—Abdominal discomfort—Methotrexate—systemic scleroderma	8.13e-05	0.000803	CcSEcCtD
Abacavir—Anorexia—Mycophenolate mofetil—systemic scleroderma	8.12e-05	0.000801	CcSEcCtD
Abacavir—Asthenia—Leflunomide—systemic scleroderma	8.11e-05	0.000801	CcSEcCtD
Abacavir—Feeling abnormal—Lisinopril—systemic scleroderma	8.01e-05	0.000791	CcSEcCtD
Abacavir—Pruritus—Leflunomide—systemic scleroderma	8e-05	0.00079	CcSEcCtD
Abacavir—Connective tissue disorder—Prednisone—systemic scleroderma	7.98e-05	0.000788	CcSEcCtD
Abacavir—Hypotension—Mycophenolate mofetil—systemic scleroderma	7.96e-05	0.000786	CcSEcCtD
Abacavir—Gastrointestinal pain—Lisinopril—systemic scleroderma	7.95e-05	0.000785	CcSEcCtD
Abacavir—Neutropenia—Methotrexate—systemic scleroderma	7.93e-05	0.000783	CcSEcCtD
Abacavir—Dizziness—Azathioprine—systemic scleroderma	7.92e-05	0.000782	CcSEcCtD
Abacavir—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	7.76e-05	0.000766	CcSEcCtD
Abacavir—Asthenia—Mycophenolic acid—systemic scleroderma	7.74e-05	0.000764	CcSEcCtD
Abacavir—Diarrhoea—Leflunomide—systemic scleroderma	7.74e-05	0.000764	CcSEcCtD
Abacavir—Urticaria—Lisinopril—systemic scleroderma	7.72e-05	0.000762	CcSEcCtD
Abacavir—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.7e-05	0.00076	CcSEcCtD
Abacavir—Abdominal pain—Lisinopril—systemic scleroderma	7.68e-05	0.000759	CcSEcCtD
Abacavir—Body temperature increased—Lisinopril—systemic scleroderma	7.68e-05	0.000759	CcSEcCtD
Abacavir—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.65e-05	0.000755	CcSEcCtD
Abacavir—Pruritus—Mycophenolic acid—systemic scleroderma	7.63e-05	0.000754	CcSEcCtD
Abacavir—Vomiting—Azathioprine—systemic scleroderma	7.61e-05	0.000752	CcSEcCtD
Abacavir—Pneumonia—Methotrexate—systemic scleroderma	7.61e-05	0.000751	CcSEcCtD
Abacavir—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	7.59e-05	0.00075	CcSEcCtD
Abacavir—Rash—Azathioprine—systemic scleroderma	7.55e-05	0.000746	CcSEcCtD
Abacavir—Dermatitis—Azathioprine—systemic scleroderma	7.54e-05	0.000745	CcSEcCtD
Abacavir—Depression—Methotrexate—systemic scleroderma	7.54e-05	0.000745	CcSEcCtD
Abacavir—Headache—Azathioprine—systemic scleroderma	7.5e-05	0.000741	CcSEcCtD
Abacavir—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	7.5e-05	0.00074	CcSEcCtD
Abacavir—Dizziness—Leflunomide—systemic scleroderma	7.48e-05	0.000739	CcSEcCtD
Abacavir—Renal failure—Methotrexate—systemic scleroderma	7.43e-05	0.000734	CcSEcCtD
Abacavir—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.4e-05	0.000731	CcSEcCtD
Abacavir—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.38e-05	0.000729	CcSEcCtD
Abacavir—Stomatitis—Methotrexate—systemic scleroderma	7.37e-05	0.000728	CcSEcCtD
Abacavir—Conjunctivitis—Methotrexate—systemic scleroderma	7.35e-05	0.000726	CcSEcCtD
Abacavir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.35e-05	0.000726	CcSEcCtD
Abacavir—Immune system disorder—Prednisone—systemic scleroderma	7.34e-05	0.000725	CcSEcCtD
Abacavir—Pain—Mycophenolate mofetil—systemic scleroderma	7.28e-05	0.000719	CcSEcCtD
Abacavir—Vomiting—Leflunomide—systemic scleroderma	7.19e-05	0.00071	CcSEcCtD
Abacavir—Alopecia—Prednisone—systemic scleroderma	7.18e-05	0.000709	CcSEcCtD
Abacavir—Hypersensitivity—Lisinopril—systemic scleroderma	7.16e-05	0.000707	CcSEcCtD
Abacavir—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.15e-05	0.000706	CcSEcCtD
Abacavir—Dizziness—Mycophenolic acid—systemic scleroderma	7.13e-05	0.000705	CcSEcCtD
Abacavir—Rash—Leflunomide—systemic scleroderma	7.13e-05	0.000704	CcSEcCtD
Abacavir—Dermatitis—Leflunomide—systemic scleroderma	7.12e-05	0.000704	CcSEcCtD
Abacavir—Nausea—Azathioprine—systemic scleroderma	7.11e-05	0.000702	CcSEcCtD
Abacavir—Headache—Leflunomide—systemic scleroderma	7.08e-05	0.0007	CcSEcCtD
Abacavir—Malnutrition—Prednisone—systemic scleroderma	7.07e-05	0.000698	CcSEcCtD
Abacavir—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.02e-05	0.000693	CcSEcCtD
Abacavir—Asthenia—Lisinopril—systemic scleroderma	6.97e-05	0.000689	CcSEcCtD
Abacavir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.96e-05	0.000688	CcSEcCtD
Abacavir—Pruritus—Lisinopril—systemic scleroderma	6.88e-05	0.000679	CcSEcCtD
Abacavir—Vomiting—Mycophenolic acid—systemic scleroderma	6.86e-05	0.000677	CcSEcCtD
Abacavir—Rash—Mycophenolic acid—systemic scleroderma	6.8e-05	0.000672	CcSEcCtD
Abacavir—Dermatitis—Mycophenolic acid—systemic scleroderma	6.8e-05	0.000671	CcSEcCtD
Abacavir—Hepatitis—Methotrexate—systemic scleroderma	6.79e-05	0.00067	CcSEcCtD
Abacavir—Urticaria—Mycophenolate mofetil—systemic scleroderma	6.76e-05	0.000668	CcSEcCtD
Abacavir—Headache—Mycophenolic acid—systemic scleroderma	6.76e-05	0.000667	CcSEcCtD
Abacavir—Pharyngitis—Methotrexate—systemic scleroderma	6.74e-05	0.000665	CcSEcCtD
Abacavir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.73e-05	0.000665	CcSEcCtD
Abacavir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.73e-05	0.000665	CcSEcCtD
Abacavir—Nausea—Leflunomide—systemic scleroderma	6.72e-05	0.000663	CcSEcCtD
Abacavir—Diarrhoea—Lisinopril—systemic scleroderma	6.65e-05	0.000657	CcSEcCtD
Abacavir—Ill-defined disorder—Prednisone—systemic scleroderma	6.56e-05	0.000648	CcSEcCtD
Abacavir—Anaemia—Prednisone—systemic scleroderma	6.54e-05	0.000645	CcSEcCtD
Abacavir—Dizziness—Lisinopril—systemic scleroderma	6.43e-05	0.000635	CcSEcCtD
Abacavir—Erythema multiforme—Methotrexate—systemic scleroderma	6.42e-05	0.000634	CcSEcCtD
Abacavir—Nausea—Mycophenolic acid—systemic scleroderma	6.41e-05	0.000633	CcSEcCtD
Abacavir—Malaise—Prednisone—systemic scleroderma	6.38e-05	0.00063	CcSEcCtD
Abacavir—Vertigo—Prednisone—systemic scleroderma	6.35e-05	0.000627	CcSEcCtD
Abacavir—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.000619	CcSEcCtD
Abacavir—Vomiting—Lisinopril—systemic scleroderma	6.18e-05	0.00061	CcSEcCtD
Abacavir—Immune system disorder—Methotrexate—systemic scleroderma	6.13e-05	0.000606	CcSEcCtD
Abacavir—Rash—Lisinopril—systemic scleroderma	6.13e-05	0.000605	CcSEcCtD
Abacavir—Convulsion—Prednisone—systemic scleroderma	6.13e-05	0.000605	CcSEcCtD
Abacavir—Dermatitis—Lisinopril—systemic scleroderma	6.12e-05	0.000604	CcSEcCtD
Abacavir—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.11e-05	0.000603	CcSEcCtD
Abacavir—Chills—Methotrexate—systemic scleroderma	6.09e-05	0.000602	CcSEcCtD
Abacavir—Headache—Lisinopril—systemic scleroderma	6.09e-05	0.000601	CcSEcCtD
Abacavir—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.02e-05	0.000595	CcSEcCtD
Abacavir—Arthralgia—Prednisone—systemic scleroderma	6.02e-05	0.000595	CcSEcCtD
Abacavir—Myalgia—Prednisone—systemic scleroderma	6.02e-05	0.000595	CcSEcCtD
Abacavir—Anxiety—Prednisone—systemic scleroderma	6e-05	0.000592	CcSEcCtD
Abacavir—Alopecia—Methotrexate—systemic scleroderma	6e-05	0.000592	CcSEcCtD
Abacavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.98e-05	0.00059	CcSEcCtD
Abacavir—Discomfort—Prednisone—systemic scleroderma	5.95e-05	0.000587	CcSEcCtD
Abacavir—Malnutrition—Methotrexate—systemic scleroderma	5.91e-05	0.000584	CcSEcCtD
Abacavir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000575	CcSEcCtD
Abacavir—Nausea—Lisinopril—systemic scleroderma	5.77e-05	0.00057	CcSEcCtD
Abacavir—Oedema—Prednisone—systemic scleroderma	5.77e-05	0.00057	CcSEcCtD
Abacavir—Anaphylactic shock—Prednisone—systemic scleroderma	5.77e-05	0.00057	CcSEcCtD
Abacavir—Infection—Prednisone—systemic scleroderma	5.73e-05	0.000566	CcSEcCtD
Abacavir—Nervous system disorder—Prednisone—systemic scleroderma	5.66e-05	0.000559	CcSEcCtD
Abacavir—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.63e-05	0.000556	CcSEcCtD
Abacavir—Skin disorder—Prednisone—systemic scleroderma	5.61e-05	0.000554	CcSEcCtD
Abacavir—Anorexia—Prednisone—systemic scleroderma	5.5e-05	0.000543	CcSEcCtD
Abacavir—Ill-defined disorder—Methotrexate—systemic scleroderma	5.48e-05	0.000541	CcSEcCtD
Abacavir—Anaemia—Methotrexate—systemic scleroderma	5.46e-05	0.000539	CcSEcCtD
Abacavir—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.41e-05	0.000535	CcSEcCtD
Abacavir—Rash—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.00053	CcSEcCtD
Abacavir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.36e-05	0.00053	CcSEcCtD
Abacavir—Headache—Mycophenolate mofetil—systemic scleroderma	5.33e-05	0.000527	CcSEcCtD
Abacavir—Malaise—Methotrexate—systemic scleroderma	5.33e-05	0.000526	CcSEcCtD
Abacavir—Vertigo—Methotrexate—systemic scleroderma	5.31e-05	0.000524	CcSEcCtD
Abacavir—Leukopenia—Methotrexate—systemic scleroderma	5.29e-05	0.000522	CcSEcCtD
Abacavir—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.26e-05	0.000519	CcSEcCtD
Abacavir—Insomnia—Prednisone—systemic scleroderma	5.22e-05	0.000515	CcSEcCtD
Abacavir—Paraesthesia—Prednisone—systemic scleroderma	5.18e-05	0.000512	CcSEcCtD
Abacavir—Cough—Methotrexate—systemic scleroderma	5.16e-05	0.000509	CcSEcCtD
Abacavir—Convulsion—Methotrexate—systemic scleroderma	5.12e-05	0.000506	CcSEcCtD
Abacavir—Nausea—Mycophenolate mofetil—systemic scleroderma	5.06e-05	0.000499	CcSEcCtD
Abacavir—Myalgia—Methotrexate—systemic scleroderma	5.03e-05	0.000497	CcSEcCtD
Abacavir—Arthralgia—Methotrexate—systemic scleroderma	5.03e-05	0.000497	CcSEcCtD
Abacavir—Decreased appetite—Prednisone—systemic scleroderma	5.02e-05	0.000495	CcSEcCtD
Abacavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5e-05	0.000493	CcSEcCtD
Abacavir—Fatigue—Prednisone—systemic scleroderma	4.98e-05	0.000491	CcSEcCtD
Abacavir—Discomfort—Methotrexate—systemic scleroderma	4.97e-05	0.000491	CcSEcCtD
Abacavir—Anaphylactic shock—Methotrexate—systemic scleroderma	4.82e-05	0.000476	CcSEcCtD
Abacavir—Infection—Methotrexate—systemic scleroderma	4.79e-05	0.000473	CcSEcCtD
Abacavir—Feeling abnormal—Prednisone—systemic scleroderma	4.76e-05	0.00047	CcSEcCtD
Abacavir—Nervous system disorder—Methotrexate—systemic scleroderma	4.73e-05	0.000467	CcSEcCtD
Abacavir—Thrombocytopenia—Methotrexate—systemic scleroderma	4.72e-05	0.000466	CcSEcCtD
Abacavir—Gastrointestinal pain—Prednisone—systemic scleroderma	4.72e-05	0.000466	CcSEcCtD
Abacavir—Skin disorder—Methotrexate—systemic scleroderma	4.69e-05	0.000463	CcSEcCtD
Abacavir—Anorexia—Methotrexate—systemic scleroderma	4.6e-05	0.000454	CcSEcCtD
Abacavir—Urticaria—Prednisone—systemic scleroderma	4.58e-05	0.000453	CcSEcCtD
Abacavir—Body temperature increased—Prednisone—systemic scleroderma	4.56e-05	0.000451	CcSEcCtD
Abacavir—Abdominal pain—Prednisone—systemic scleroderma	4.56e-05	0.000451	CcSEcCtD
Abacavir—Hypotension—Methotrexate—systemic scleroderma	4.51e-05	0.000445	CcSEcCtD
Abacavir—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.39e-05	0.000434	CcSEcCtD
Abacavir—Insomnia—Methotrexate—systemic scleroderma	4.36e-05	0.000431	CcSEcCtD
Abacavir—Paraesthesia—Methotrexate—systemic scleroderma	4.33e-05	0.000428	CcSEcCtD
Abacavir—Dyspnoea—Methotrexate—systemic scleroderma	4.3e-05	0.000425	CcSEcCtD
Abacavir—Hypersensitivity—Prednisone—systemic scleroderma	4.25e-05	0.00042	CcSEcCtD
Abacavir—Decreased appetite—Methotrexate—systemic scleroderma	4.19e-05	0.000414	CcSEcCtD
Abacavir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.16e-05	0.000411	CcSEcCtD
Abacavir—Fatigue—Methotrexate—systemic scleroderma	4.16e-05	0.000411	CcSEcCtD
Abacavir—Asthenia—Prednisone—systemic scleroderma	4.14e-05	0.000409	CcSEcCtD
Abacavir—Pain—Methotrexate—systemic scleroderma	4.12e-05	0.000407	CcSEcCtD
Abacavir—Pruritus—Prednisone—systemic scleroderma	4.08e-05	0.000403	CcSEcCtD
Abacavir—Feeling abnormal—Methotrexate—systemic scleroderma	3.97e-05	0.000393	CcSEcCtD
Abacavir—Diarrhoea—Prednisone—systemic scleroderma	3.95e-05	0.00039	CcSEcCtD
Abacavir—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.94e-05	0.000389	CcSEcCtD
Abacavir—Urticaria—Methotrexate—systemic scleroderma	3.83e-05	0.000378	CcSEcCtD
Abacavir—Dizziness—Prednisone—systemic scleroderma	3.82e-05	0.000377	CcSEcCtD
Abacavir—Abdominal pain—Methotrexate—systemic scleroderma	3.81e-05	0.000377	CcSEcCtD
Abacavir—Body temperature increased—Methotrexate—systemic scleroderma	3.81e-05	0.000377	CcSEcCtD
Abacavir—Vomiting—Prednisone—systemic scleroderma	3.67e-05	0.000362	CcSEcCtD
Abacavir—Rash—Prednisone—systemic scleroderma	3.64e-05	0.000359	CcSEcCtD
Abacavir—Dermatitis—Prednisone—systemic scleroderma	3.64e-05	0.000359	CcSEcCtD
Abacavir—Headache—Prednisone—systemic scleroderma	3.62e-05	0.000357	CcSEcCtD
Abacavir—Hypersensitivity—Methotrexate—systemic scleroderma	3.55e-05	0.000351	CcSEcCtD
Abacavir—Asthenia—Methotrexate—systemic scleroderma	3.46e-05	0.000342	CcSEcCtD
Abacavir—Nausea—Prednisone—systemic scleroderma	3.43e-05	0.000339	CcSEcCtD
Abacavir—Pruritus—Methotrexate—systemic scleroderma	3.41e-05	0.000337	CcSEcCtD
Abacavir—Diarrhoea—Methotrexate—systemic scleroderma	3.3e-05	0.000326	CcSEcCtD
Abacavir—Dizziness—Methotrexate—systemic scleroderma	3.19e-05	0.000315	CcSEcCtD
Abacavir—Vomiting—Methotrexate—systemic scleroderma	3.07e-05	0.000303	CcSEcCtD
Abacavir—Rash—Methotrexate—systemic scleroderma	3.04e-05	0.0003	CcSEcCtD
Abacavir—Dermatitis—Methotrexate—systemic scleroderma	3.04e-05	0.0003	CcSEcCtD
Abacavir—Headache—Methotrexate—systemic scleroderma	3.02e-05	0.000298	CcSEcCtD
Abacavir—Nausea—Methotrexate—systemic scleroderma	2.86e-05	0.000283	CcSEcCtD
